THIRD GENERATION SEQUENCING MARKET ANALYSIS

Market News

Recent Developments

New product launches

• On March 14, 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced the availability of its first product based on its revolutionary Illumina Complete Long Read technology. The Illumina Complete Long Read Prep, Human high-performance, long-read human whole-genome sequencing (WGS) test is compatible with the Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems.
• In November 2022, Element Biosciences, Inc., a developer of an innovative DNA sequencing platform disrupting the genomics industry, announced the availability of its Element LoopSeq long-read sequencing technology kits for AVITI, giving the Element AVITI System the ability to perform both short- and long-read sequencing on the same instrument. Element is the first firm to own a general-purpose long-read technology that is powered by its native short-read sequencer.
• In October 2022, PacBio, a leading provider of high-quality, highly accurate sequencing solutions, announced the Revio long-read sequencing system, which will allow customers to rapidly scale their use of PacBio's renowned HiFi sequencing technology. Revio is intended to allow users to sequence up to 1,300 human entire genomes each year at 30-fold coverage for less than US$ 1,000 per genome.

• Merger, and collaborations

• On August 7, 2023, PacBio, a leading developer of high-quality, highly accurate sequencing solutions, and GeneDx, a leader in improving health outcomes through genomic and clinical insights, announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.
• On May 1, 2023, Aptorum Group Limited, a pharmaceutical company, announced that its wholly owned subsidiary Aptorum Therapeutics Limited has entered into a non-binding Letter of Intent and Term Sheet to merge its 100% subsidiary, Paths Innovation Limited, and its underlying business with Universal Sequencing Technology Corporation, a San Diego and Boston-based US company dedicated to the development and commercialization of advanced proprietary DNA sequencing technologies.